BioProtect devices are a family of patent-protected biodegradable biological implants that are introduced by minimally invasive procedures at the desired location under the guidance of US, CT, MRI, fluoroscopy, laparoscopy, or left in place at the end of a surgical intervention.
BioProtect's first product (SpaceGuard BalloonTM) is indicated for prostate cancer patients undergoing radiotherapy treatments. The implant separates the prostate from healthy tissues and organs surrounding the prostate and thereby minimizes the applied radiation to these organs. The implant is designed to dissolve after 3-6 months, corresponding to the standard duration of radiotherapy procedures for prostate cancer. The implant is made of well know biodegradable material routinely used in existing medically approved devices (such as pericardial patch). The balloon insertion technique is based on a well-established technique commonly used by urologists at outpatient centers.
A multi center clinical trial in the US, Europe and Israel has been taking place since Q109 with 24 patients enrolled to date.

BioProtect is also developing a solution for slow drug release using its platform. The balloon can be used for both systemic and localized drug delivery. Systemically, the device can be used as a delivery solution for unstable hormones like: Growth Hormone, Erythropoietin and many more. When used locally, the device can be used as a complementary treatment for the specific balloon application.

BioProtect was founded with Xenia in 2004, matured incubator in 2006 and raised follow on funds from leading physicians and investors in Israel and the US.

TEAM

Shaul Shohat, Co-founder, CEO
M.Sc in analytical chemistry, more than 15 years experience in development of medical devices.

Dr. Adrian Paz, MD., Co-founder, active Board Member
Chief of the urological laparoscopic services at Barzilai medical center, Ashkelon.

Prof. Abraham Domb PhD., Co-Founder
World renown expert in medical biomaterials. Professor & Chairman: Dept. Medicine, Chemistry and Natural products, School of Pharmacy, The Hebrew University of Jerusalem.

Dr. Yossi Muncher, VP Clinical Affairs
More than 15 years in VP positions for medical device companies in the regulatory and clinical fields.

Dr. Rami Ben-Yosef, MD., Clinical Oncology consultant
Head of Uro-Oncology Service, Department of Oncology, Souraski Medical Center, Tel-Aviv.

Adivsory Board

Prof. Michael Zelefski, MD., Head of Advisory Board
internationally recognized Radiation Oncologist; Chief Brachytherapy Service, Memorial Sloan-Kettering Cancer Center in New York.

Prof. Benjamin Corn, MD.,
Head of Institute of Radiotherapy, Souraski Medical Center, Tel Aviv. Former CEO Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX)